Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles from Sweden
Based on 465 articles published since 2008

These are the 465 published articles about Coronary Artery Disease that originated from Sweden during 2008-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19
1 Editorial Lung Function and Coronary Artery Disease Risk. 2018

Nowak, Christoph. ·Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Huddinge, Sweden. christoph.nowak@ki.se. ·Circ Genom Precis Med · Pubmed #29650768.

ABSTRACT: -- No abstract --

2 Editorial Coronary Artery Disease and Its Risk Factors: Leveraging Shared Genetics to Discover Novel Biology. 2016

Quertermous, Thomas / Ingelsson, Erik. ·From the Division of Cardiovascular Medicine, Department of Medicine (T.Q., E.I.), Cardiovascular Institute (T.Q., E.I.), Stanford University School of Medicine, CA · and Molecular Epidemiology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden (E.I.). ·Circ Res · Pubmed #26837740.

ABSTRACT: -- No abstract --

3 Editorial Regulatory T cells: getting to the heart of the matter. 2016

Nilsson, J. ·Department of Clinical Sciences, Lund University, Malmö, Sweden. ·J Intern Med · Pubmed #26514991.

ABSTRACT: -- No abstract --

4 Editorial Serum S100A12: A Risk Marker or Risk Factor of Vascular Calcification in Chronic Kidney Disease. 2015

Lindholm, Bengt. ·Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. ·Am J Nephrol · Pubmed #26278719.

ABSTRACT: -- No abstract --

5 Editorial Obstructive sleep apnoea and cardiovascular calcification. 2015

Bäck, Magnus / Stanke-Labesque, Françoise. ·Translational Cardiology, Karolinska Institutet, Stockholm, Sweden Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden. · Université Grenoble Alpes, Grenoble, France INSERM U1042, HP2,Grenoble, France Department of Pharmacology, CHU, Grenoble, France. ·Thorax · Pubmed #26272928.

ABSTRACT: -- No abstract --

6 Editorial Women with nonobstructive coronary artery disease are not necessarily healthy. 2015

Schenck-Gustafsson, Karin / Johnston, Nina. ·1 Department of Cardiology Centre for Gender Medicine, Karolinska University Hospital , Stockholm, Sweden . ·J Womens Health (Larchmt) · Pubmed #25973797.

ABSTRACT: -- No abstract --

7 Editorial Recognition of resting heart calcification as a means to an end: an eye-opener in the application of dobutamine stress echocardiography in subjects with chest pain. 2015

Saha, Samir K / Govind, Satish C. ·Karolinska Institutet, Sundsvall, Sweden. · Narayana Institute of Cardiac Sciences, Bangalore, India. ·Echocardiography · Pubmed #25728209.

ABSTRACT: -- No abstract --

8 Editorial Computerized decision making in myocardial perfusion SPECT: The new era in nuclear cardiology? 2015

Trägårdh, Elin / Carlsson, Marcus / Edenbrandt, Lars. ·Clinical Physiology and Nuclear Medicine, Lund University, Skåne University Hospital, Malmö, Sweden. elin.tragardh@med.lu.se. · Clinical Physiology and Nuclear Medicine, Lund University, Skåne University Hospital, Lund, Sweden. · Clinical Physiology and Nuclear Medicine, Lund University, Skåne University Hospital, Malmö, Sweden. ·J Nucl Cardiol · Pubmed #25500801.

ABSTRACT: -- No abstract --

9 Editorial Low degree of shared genetic susceptibility to coronary artery disease and venous thromboembolism. 2014

Zöller, Bengt. ·Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, Sweden. Electronic address: bengt.zoller@med.lu.se. ·Thromb Res · Pubmed #24985037.

ABSTRACT: -- No abstract --

10 Review Bilateral Versus Single Internal Thoracic Artery Grafts. 2018

Persson, Michael / Sartipy, Ulrik. ·Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. · Section of Cardiothoracic Surgery, Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden. · Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Ulrik.Sartipy@karolinska.se. · Section of Cardiothoracic Surgery, Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden. Ulrik.Sartipy@karolinska.se. ·Curr Cardiol Rep · Pubmed #29362968.

ABSTRACT: PURPOSE OF REVIEW: Several advances have been made in recent years to improve outcome for patients with coronary artery disease. One of the most debated topics regarding surgical treatment with coronary artery bypass grafting (CABG) is graft selection. This review aims to present the current status and scientific evidence for bilateral internal thoracic artery (BITA) grafting. RECENT FINDINGS: Observational studies and pooled analyses suggest that BITA grafting is associated with improved survival. Early results from a large randomized controlled trial report safety and efficacy of the method. The improved survival might be amplified in select groups, but with an increase in sternal wound-related complications. The benefit of BITA grafts seems to remain to an approximate age of 69 years at surgery. CABG with BITA grafts is likely associated with improved long-term survival at a cost of an increase in sternal wound infections. Ten-year results from the Arterial Revascularization Trial are expected in 2018, providing the best evidence regarding the method yet. Early results show it is a safe method in most patient categories considerable for CABG.

11 Review Culprit Vessel-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment-Elevation Myocardial Infarction: A Collaborative Meta-Analysis. 2017

Kolte, Dhaval / Sardar, Partha / Khera, Sahil / Zeymer, Uwe / Thiele, Holger / Hochadel, Matthias / Radovanovic, Dragana / Erne, Paul / Hambraeus, Kristina / James, Stefan / Claessen, Bimmer E / Henriques, Jose P S / Mylotte, Darren / Garot, Philippe / Aronow, Wilbert S / Owan, Theophilus / Jain, Diwakar / Panza, Julio A / Frishman, William H / Fonarow, Gregg C / Bhatt, Deepak L / Aronow, Herbert D / Abbott, J Dawn. ·From the Department of Medicine, Division of Cardiology, Brown University, Providence, RI (D.K., H.D.A., J.D.A.) · Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City (P.S., T.O.) · Department of Medicine, Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla (S.K., W.S.A., D.J., J.A.P., W.H.F.) · Department of Cardiology, Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z., M.H.) · Department of Cardiology, University Heart Center Lübeck, Medical Clinic II, University Hospital Schleswig-Holstein, Germany (H.T.) · German Cardiovascular Research Center (DZHK), Partner Site Hamburg/Kiel/Lübeck, Germany (H.T.) · AMIS Plus Data Center, University of Zurich, Switzerland (D.R., P.E.) · Department of Cardiology, Falun Hospital, Sweden (K.H.) · Department of Medical Sciences, Uppsala University, Sweden (K.H., S.J.) · Department of Cardiology, Academic Medical Center, University of Amsterdam, the Netherlands (B.E.C., J.P.S.H.) · Department of Cardiology, Galway University Hospital, SAOLTA Healthcare Group, National University of Ireland (D.M.) · Department of Cardiology, Ramsay Générale de Santé, Institut Cardiovasculaire Paris Sud, Hopital Privé Jacques Cartier, Massy, France (P.G.) · Department of Medicine, Division of Cardiology, David-Geffen School of Medicine, University of California at Los Angeles (G.C.F.) · and Department of Medicine, Division of Cardiology, Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.). ·Circ Cardiovasc Interv · Pubmed #29146672.

ABSTRACT: BACKGROUND: The optimal revascularization strategy in patients with multivessel disease presenting with cardiogenic shock complicating ST-segment-elevation myocardial infarction remains unknown. METHODS AND RESULTS: Databases were searched from 1999 to October 2016. Studies comparing immediate/single-stage multivessel percutaneous coronary intervention (MV-PCI) versus culprit vessel-only PCI (CO-PCI) in patients with multivessel disease, ST-segment-elevation myocardial infarction, and cardiogenic shock were included. Primary end point was short-term (in-hospital or 30 days) mortality. Secondary end points included long-term mortality, cardiovascular death, reinfarction, and repeat revascularization. Safety end points were in-hospital stroke, renal failure, and major bleeding. The meta-analysis included 11 nonrandomized studies and 5850 patients (1157 MV-PCI and 4693 CO-PCI). There was no significant difference in short-term mortality with MV-PCI versus CO-PCI (odds ratio [OR], 1.08; 95% confidence interval [CI], 0.81-1.43; CONCLUSIONS: This meta-analysis of nonrandomized studies suggests that in patients with cardiogenic shock complicating ST-segment-elevation myocardial infarction, there may be no significant benefit with single-stage MV-PCI compared with CO-PCI. Given the limitations of observational data, randomized trials are needed to determine the role of MV-PCI in this setting.

12 Review Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 2017

Patrono, Carlo / Morais, Joao / Baigent, Colin / Collet, Jean-Philippe / Fitzgerald, Desmond / Halvorsen, Sigrun / Rocca, Bianca / Siegbahn, Agneta / Storey, Robert F / Vilahur, Gemma. ·Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. Electronic address: carlo.patrono@unicatt.it. · Division of Cardiology, Santo Andre's Hospital, Leiria, Portugal. · MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom. · Sorbonne Université Paris 6, ACTION Study Group, Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), INSERM UMRS 1166, Paris, France. · University of Limerick, Limerick, Ireland. · Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway. · Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. · Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden. · Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, United Kingdom. · Cardiovascular Science Institute-ICCC IIB-Sant Pau, CiberCV, Hospital de Sant Pau, Barcelona, Spain. ·J Am Coll Cardiol · Pubmed #28958334.

ABSTRACT: Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their recurrence. Their role in the primary prevention of atherothrombosis remains controversial because of the uncertain balance of the potential benefits and risks when combined with other preventive strategies. The aim of this consensus document is to review the evidence for the efficacy and safety of antiplatelet drugs, and to provide practicing cardiologists with an updated instrument to guide their choice of the most appropriate antiplatelet strategy for the individual patient presenting with different clinical manifestations of coronary atherothrombosis, in light of comorbidities and/or interventional procedures.

13 Review The Evolving Future of Instantaneous Wave-Free Ratio and Fractional Flow Reserve. 2017

Götberg, Matthias / Cook, Christopher M / Sen, Sayan / Nijjer, Sukhjinder / Escaned, Javier / Davies, Justin E. ·Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden. Electronic address: Matthias.gotberg@med.lu.se. · Hammersmith Hospital, Imperial College London, London, United Kingdom. · Hospital Clínico San Carlos, Madrid, Spain. ·J Am Coll Cardiol · Pubmed #28882237.

ABSTRACT: In this review, the authors reflect upon the role of coronary physiology in the modern management of coronary artery disease. They critically appraise the scientific background of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR), from early experimental studies to validation studies against indexes of ischemia, to clinical trials assessing outcome. At this important juncture for the field, the authors make predictions for the future of physiological stenosis assessment, outlining developments for both iFR and FFR in new clinical domains beyond the confines of stable angina. With a focus on the evolving future of iFR and FFR, the authors describe how physiological assessment with iFR may advance its application from simply justifying to guiding revascularization.

14 Review Impact of Sex on Cardiac Troponin Concentrations-A Critical Appraisal. 2017

Eggers, Kai M / Lindahl, Bertil. ·Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. kai.eggers@ucr.uu.se. · Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. ·Clin Chem · Pubmed #28630238.

ABSTRACT: BACKGROUND: The use of sex-specific cutoffs for cardiac troponin (cTn) is currently debated. Although endorsed by scientific working groups, concerns have been raised that sex-specific cutoffs may have only a small clinical effect at the cost of increased complexity in decision-making. METHODS: We reviewed studies investigating the interrelations between high-sensitivity (hs) cTn results and sex, diagnoses, and outcome. Investigated populations included community-dwelling subjects and patients with stable angina, congestive heart failure, or acute chest pain including those with acute coronary syndromes. RESULTS: Men usually have higher hs-cTn concentrations compared with women, regardless of the assessed population or the applied assay. The distribution and prognostic implications of hs-cTn concentrations indicate that women have a broader cardiovascular risk panorama compared with men, particularly at lower hs-cTn concentrations. At higher concentrations, particularly above the 99th percentile, this variation is often attenuated. Sex-specific hs-cTn 99th percentiles have so far shown clinical net benefit in only 1 study assessing patients with chest pain. However, several methodological aspects need to be considered when interpreting study results, e.g., issues related to the determination of the 99th percentiles, the selection bias, and the lack of prospective and sufficiently powered analyses. CONCLUSIONS: Available studies do not show a consistent clinical superiority of sex-specific hs-cTn 99th percentiles. This may reflect methodological aspects. However, from a pathobiological perspective, the use of sex-specific hs-cTn 99th percentiles makes sense for the ruling in of myocardial infarction. We propose a new approach to hs-cTn 99th cutoffs taking into account the analytical properties of the used assays.

15 Review Recent Advances in Cardiovascular Magnetic Resonance: Techniques and Applications. 2017

Salerno, Michael / Sharif, Behzad / Arheden, Håkan / Kumar, Andreas / Axel, Leon / Li, Debiao / Neubauer, Stefan. ·From the Cardiovascular Division, Department of Medicine, Department of Radiology and Medical Imaging, and Department of Biomedical Engineering, University of Virginia Health System, Charlottesville (M.S.) · Biomedical Imaging Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA (B.S., D.L.) · Department of Clinical Sciences, Clinical Physiology, Lund University, Skane University Hospital, Sweden (H.A.) · Cardiology Division, Department of Medicine, Northern Ontario School of Medicine, Sudbury, Canada (A.K.) · Department of Radiology and Department of Medicine, New York University, New York (L.A.) · and Division of Cardiovascular Medicine, Oxford Center for Clinical Magnetic Resonance Research, University of Oxford, London, United Kingdom (S.N.). ·Circ Cardiovasc Imaging · Pubmed #28611116.

ABSTRACT: Cardiovascular magnetic resonance imaging has become the gold standard for evaluating myocardial function, volumes, and scarring. Additionally, cardiovascular magnetic resonance imaging is unique in its comprehensive tissue characterization, including assessment of myocardial edema, myocardial siderosis, myocardial perfusion, and diffuse myocardial fibrosis. Cardiovascular magnetic resonance imaging has become an indispensable tool in the evaluation of congenital heart disease, heart failure, cardiac masses, pericardial disease, and coronary artery disease. This review will highlight some recent novel cardiovascular magnetic resonance imaging techniques, concepts, and applications.

16 Review Systematic review of cost-effectiveness of myocardial perfusion scintigraphy in patients with ischaemic heart disease: A report from the cardiovascular committee of the European Association of Nuclear Medicine. Endorsed by the European Association of Cardiovascular Imaging. 2017

Trägårdh, Elin / Tan, Siok Swan / Bucerius, Jan / Gimelli, Alessia / Gaemperli, Oliver / Lindner, Oliver / Agostini, Denis / Übleis, Christopher / Sciagrà, Roberto / Slart, Riemer H / Underwood, S Richard / Hyafil, Fabien / Hacker, Marcus / Verberne, Hein J. ·Clinical Physiology and Nuclear Medicine, Lund University and Skåne University Hospital, Inga Marie Nilssons gata 49, 205 02 Malmö, Sweden. · Erasmus University Rotterdam, Institute for Medical Technology Assessment, Burgemeester Oudlaan 50, 3062 PA, Rotterdam, The Netherlands. · Department of Nuclear Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, PO Box 5800, 6202 AZ, Maastricht, The Netherlands. · Department of Nuclear Medicine, University Hospital, Pauwelsstrasse 30, 52074 Aachen, Germany. · Fondazione Toscana Gabriele Monasterio, Via Guiseppe Moruzzi 1, 56124 Pisa, Italy. · Cardiac Imaging and Interventional Cardiology, University Heart Centre, Rämistrasse 100, 8091 Zurich, Switzerland. · Institute of Radiology, Nuclear Medicine and Molecular Imaging, Heart and Diabetes Centre North Rhine-Westphalia, University Hospital of the Ruhr University Bochum, Georgstrasse 11, 32545 Bad Oeynhausen, Germany. · Department of Nuclear Medicine, University Hospital of Caen and Normandie Université, Avenue de la Côte de Nacre, 104009 CEDEX 1 Caen, France. · Department of Clinical Radiology, Ludwig-Maximilians Universität München, Marchioninistrasse 15, 81377 Munich, Germany. · Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Largo Brambilla 3, 50134 Florence, Italy. · Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, PO Box 30001, 9700 RB, Groningen, The Netherlands. · Department of Biomedical Photonic Imaging, University of Twente, PO Box 217, 7500 AE, Enschede, The Netherlands. · National Heart and Lung Institute, Imperial College London, Royal Brompton and Harefield Hospitals, Sydney Street, SW3 6NP, London, UK. · Department of Nuclear Medicine, Bichat University Hospital, DHU FIRE, Inserm 1148, University of Paris Diderot, 46 rue Henri Huchard, 75018 Paris, France. · Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. · Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. ·Eur Heart J Cardiovasc Imaging · Pubmed #28549119.

ABSTRACT: Coronary artery disease (CAD) is a major cause of death and disability. Several diagnostic tests, such as myocardial perfusion scintigraphy (MPS), are accurate for the detection of CAD, as well as having prognostic value for the prediction of cardiovascular events. Nevertheless, the diagnostic and prognostic value of these tests should be cost-effective and should lead to improved clinical outcome. We have reviewed the literature on the cost-effectiveness of MPS in different circumstances: (i) the diagnosis and management of CAD; (ii) comparison with exercise electrocardiography (ECG) and other imaging tests; (iii) as gatekeeper to invasive coronary angiography (ICA), (iv) the impact of appropriate use criteria; (v) acute chest pain, and (vi) screening of asymptomatic patients with type-2 diabetes. In total 57 reports were included. Although most non-invasive imaging tests are cost-effective compared with alternatives, the data conflict on which non-invasive strategy is the most cost-effective. Different definitions of cost-effectiveness further confound the subject. Computer simulations of clinical diagnosis and management are influenced by the assumptions made. For instance, diagnostic accuracy is often defined against an anatomical standard that is wrongly assumed to be perfect. Conflicting data arise most commonly from these incorrect or differing assumptions.

17 Review Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. 2017

Costa, Francesco / van Klaveren, David / James, Stefan / Heg, Dik / Räber, Lorenz / Feres, Fausto / Pilgrim, Thomas / Hong, Myeong-Ki / Kim, Hyo-Soo / Colombo, Antonio / Steg, Philippe Gabriel / Zanchin, Thomas / Palmerini, Tullio / Wallentin, Lars / Bhatt, Deepak L / Stone, Gregg W / Windecker, Stephan / Steyerberg, Ewout W / Valgimigli, Marco / Anonymous4670899. ·Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland; Erasmus University Medical Center, Rotterdam, Netherlands; Department of Clinical and Experimental Medicine, Policlinic "G Martino", University of Messina, Messina, Italy. · Erasmus University Medical Center, Rotterdam, Netherlands; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA. · Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. · Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. · Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland. · Istituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil. · Severance Cardiovascular Hospital, Yonsei University College of Medicine and Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea. · Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. · EMO-GVM Centro Cuore Columbus, Milan, Italy; Interventional Cardiology Department, San Raffaele Scientific Institute, Milan, Italy. · Department of Cardiology, Assistance Publique-Hôpitaux de Paris (AP-HP), Bichat Hospital, Paris, France. · Dipartimento Cardio-Toraco-Vascolare, University of Bologna, Bologna, Italy. · Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA, USA. · Columbia University Medical Center/New York-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY, USA. · Erasmus University Medical Center, Rotterdam, Netherlands. · Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland; Erasmus University Medical Center, Rotterdam, Netherlands. Electronic address: marco.valgimigli@insel.ch. ·Lancet · Pubmed #28290994.

ABSTRACT: BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y METHODS: A total of 14 963 patients treated with DAPT after coronary stenting-largely consisting of aspirin and clopidogrel and without indication to oral anticoagulation-were pooled at a single-patient level from eight multicentre randomised clinical trials with independent adjudication of events. Using Cox proportional hazards regression, we identified predictors of out-of-hospital Thrombosis in Myocardial Infarction (TIMI) major or minor bleeding stratified by trial, and developed a numerical bleeding risk score. The predictive performance of the novel score was assessed in the derivation cohort and validated in patients treated with percutaneous coronary intervention from the PLATelet inhibition and patient Outcomes (PLATO) trial (n=8595) and BernPCI registry (n=6172). The novel score was assessed within patients randomised to different DAPT durations (n=10 081) to identify the effect on bleeding and ischaemia of a long (12-24 months) or short (3-6 months) treatment in relation to baseline bleeding risk. FINDINGS: The PRECISE-DAPT score (age, creatinine clearance, haemoglobin, white-blood-cell count, and previous spontaneous bleeding) showed a c-index for out-of-hospital TIMI major or minor bleeding of 0·73 (95% CI 0·61-0·85) in the derivation cohort, and 0·70 (0·65-0·74) in the PLATO trial validation cohort and 0·66 (0·61-0·71) in the BernPCI registry validation cohort. A longer DAPT duration significantly increased bleeding in patients at high risk (score ≥25), but not in those with lower risk profiles (p INTERPRETATION: The PRECISE-DAPT score is a simple five-item risk score, which provides a standardised tool for the prediction of out-of-hospital bleeding during DAPT. In the context of a comprehensive clinical evaluation process, this tool can support clinical decision making for treatment duration. FUNDING: None.

18 Review Role of PVAT in coronary atherosclerosis and vein graft patency: friend or foe? 2017

Fernández-Alfonso, M S / Gil-Ortega, M / Aranguez, I / Souza, D / Dreifaldt, M / Somoza, B / Dashwood, M R. ·Instituto Pluridisciplinar and Facultad de Farmacia, Universidad Complutense, Madrid, Spain. · Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad CEU-San Pablo, Madrid, Spain. · Department of Cardiothoracic and Vascular Surgery and University Health Care Research Center, School of Medical Sciences, Örebro University, Örebro, Sweden. · Royal Free Hospital Campus, University College Medical School, London, UK. ·Br J Pharmacol · Pubmed #28150299.

ABSTRACT: Perivascular adipose tissue (PVAT) releases numerous factors and adipokines with paracrine effects on both vascular structure and function. These effects are variable as they depend on regional differences in PVAT among blood vessels and vary with changes in adiposity. There is considerable evidence demonstrating an association between coronary PVAT and the development and progression of coronary artery disease, which is associated with inflammation, oxidative stress, angiogenesis, vascular remodelling and blood clotting. However, PVAT also has a protective role in vascular grafts, especially the no-touch saphenous vein, in patients undergoing coronary artery bypass. This beneficial influence of PVAT involves factors such as adipocyte-derived relaxing factor, nitric oxide (NO), leptin, adiponectin, prostanoids, hydrogen sulphide and neurotransmitters, as well as mechanical protection. This article aims to highlight and compare the dual role of PVAT in the development and progression of coronary atherosclerosis, as well as in increased graft patency. Different deleterious and protective mechanisms of PVAT are also discussed and the inside-outside signalling paradigm of atherosclerosis development re-evaluated. The bidirectional communication between the arterial and venous wall and their surrounding PVAT, where signals originating from the vascular wall or lumen can affect PVAT phenotype, has been shown to be very complex. Moreover, signals from PVAT also influence the structure and function of the vascular wall in a paracrine manner. LINKED ARTICLES: This article is part of a themed section on Molecular Mechanisms Regulating Perivascular Adipose Tissue - Potential Pharmacological Targets? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.20/issuetoc.

19 Review Coronary Artery Fistulas: Case Series and Literature Review. 2017

Karazisi, Christina / Eriksson, Peter / Dellborg, Mikael. ·Section of Cardiology, Department of Medicine, Sahlgrenska University Hospital, Östra, Gothenburg, Sweden. ·Cardiology · Pubmed #27577264.

ABSTRACT: Congenital coronary artery fistulas are rare anomalies. As coronary angiography and multidetector computed tomography have become more accessible, they have been increasingly used in the investigation of chest pain and heart failure. Coronary artery fistulas are often an incidental finding, which raises the question of how patients with this condition should be managed. Intervention with either transcatheter closure or surgical closure is often technically possible. Many patients are asymptomatic early after closure. However, follow-up studies have shown post-closure sequelae, such as residual leakage, thrombosis with or without myocardial infarction, and coronary stenosis. Therefore, there has been a shift from intervention towards watchful waiting in asymptomatic patients. In this article, we review the published literature on the natural history and treatment outcomes in individuals with coronary artery fistulas. We present case reports from our clinic and discuss the management of incidental findings of coronary artery fistulas.

20 Review Common genetic risk factors for coronary artery disease: new opportunities for prevention? 2017

Hamrefors, Viktor. ·Department of Clinical Sciences, Faculty of Medicine, Lund University, Malmö, Sweden. · Department of Medical Imaging and Physiology, Skåne University Hospital, Malmö, Sweden. ·Clin Physiol Funct Imaging · Pubmed #26278888.

ABSTRACT: Atherosclerotic cardiovascular disease (CVD) is a leading cause of mortality and morbidity worldwide, with coronary artery disease (CAD) being the single leading cause of death. Better control of risk factors, enhanced diagnostic techniques and improved medical therapies have all substantially decreased the mortality of CAD in developed countries. However, CAD and other forms of atherosclerotic CVD are projected to remain the leading cause of death by 2030 and we face a number of challenges if the outcomes of CAD are to be further improved. The fact that a substantial fraction of high-risk subjects do not reach treatment goals for important risk factors is one of these challenges. At the same time, there is also a non-negotiable fraction of 'concealed' high-risk subjects who are not detected by current risk algorithms and diagnostic modalities. In recent years, we have started to rapidly increase our knowledge of the framework of common genetics underlying CAD and atherosclerotic CVD in the population. In conjunction with modern diagnostic and therapeutic options, this new genetic knowledge may provide a valuable tool for further improvements in prevention. This review summarizes the recent findings from the search for common genetic risk factors for CAD. Furthermore, the author discusses how such recent findings could potentially be used in a number of clinical applications within CAD prevention, including in clinical risk stratification, in prediction of drug treatment response and in the search for targets for novel preventive therapies.

21 Review Percutaneous Coronary Intervention for Bifurcation Lesions. 2016

Redfors, Björn / Généreux, Philippe. ·Clinical Trial Center, Cardiovascular Research Foundation, 111 East 59th Street, New York, NY 10022, USA; Department of Cardiology, Sahlgrenska University Hospital, Bruna Straket 16, 413 45 Gothenburg, Sweden. · Clinical Trial Center, Cardiovascular Research Foundation, 111 East 59th Street, New York, NY 10022, USA; Department of Cardiology, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, 5400, boul. Gouin Ouest, Montréal, Québec H4J 1C5, Canada. Electronic address: pgenereux@crf.org. ·Interv Cardiol Clin · Pubmed #28582201.

ABSTRACT: This article summarizes treatment alternatives for coronary bifurcation lesions. It also reviews current definitions and classifications pertaining to bifurcation lesions and provides an overview of the impact of bifurcation lesions on clinical outcomes.

22 Review Diabetes and Hypertension Consistently Predict the Presence and Extent of Coronary Artery Calcification in Symptomatic Patients: A Systematic Review and Meta-Analysis. 2016

Nicoll, Rachel / Zhao, Ying / Ibrahimi, Pranvera / Olivecrona, Gunilla / Henein, Michael. ·Department of Public Health and Clinical Medicine, Umea University and Heart Centre, Umea SE-901-87, Sweden. rachelnicoll25@gmail.com. · Department of Ultrasound, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. yingzhaoecho@163.com. · Department of Public Health and Clinical Medicine, Umea University and Heart Centre, Umea SE-901-87, Sweden. pranvera_i86@hotmail.com. · Department of Medical Biosciences, Umea University, Umea SE-901-87, Sweden. gunilla.olivecrona@medbio.umu.se. · Department of Public Health and Clinical Medicine, Umea University and Heart Centre, Umea SE-901-87, Sweden. michael.henein@umu.se. ·Int J Mol Sci · Pubmed #27608015.

ABSTRACT: BACKGROUND: The relationship of conventional cardiovascular risk factors (age, gender, ethnicity, diabetes, dyslipidaemia, hypertension, obesity, exercise, and the number of risk factors) to coronary artery calcification (CAC) presence and extent has never before been assessed in a systematic review and meta-analysis. METHODS: We included only English language studies that assessed at least three conventional risk factors apart from age, gender, and ethnicity, but excluded studies in which all patients had another confirmed condition such as renal disease. RESULTS: In total, 10 studies, comprising 15,769 patients, were investigated in the systematic review and seven studies, comprising 12,682 patients, were included in the meta-analysis, which demonstrated the importance of diabetes and hypertension as predictors of CAC presence and extent, with age also predicting CAC presence. Male gender, dyslipidaemia, family history of coronary artery disease, obesity, and smoking were overall not predictive of either CAC presence or extent, despite dyslipidaemia being a key risk factor for coronary artery disease (CAD). CONCLUSION: Diabetes and hypertension consistently predict the presence and extent of CAC in symptomatic patients.

23 Review Association between preoperative depression and long-term survival following coronary artery bypass surgery - A systematic review and meta-analysis. 2016

Stenman, Malin / Holzmann, Martin J / Sartipy, Ulrik. ·Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Electronic address: Malin.Stenman@ki.se. · Department of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Internal Medicine, Karolinska Institutet, Stockholm, Sweden. · Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. ·Int J Cardiol · Pubmed #27505334.

ABSTRACT: BACKGROUND: Depression is common in patients with cardiovascular disease. The importance of preoperative depression for long-term survival following coronary artery bypass grafting (CABG) is not well known. The aim was to provide a summary estimate of the association between preoperative depression and long-term survival in adults who underwent CABG. METHODS: We did a systematic search of MEDLINE, EMBASE, Cochrane Library, PsycINFO, Web of Science, and PubMed from inception to November, 2015, including cohort studies with at least one month of follow-up that reported hazard ratios (HR) and 95% confidence intervals (CI) for long-term all-cause mortality following CABG in patients with preoperative depression compared to non-depressed patients. Two reviewers independently extracted data on populations, exposure, outcome, risk of bias, and quality of evidence. We calculated HR and 95% CIs for all-cause mortality using random-effects meta-analyses and performed subgroup and sensitivity analyses. RESULTS: Seven studies were included with a combined study population of 89,490 patients (4002 depressed/85,488 non-depressed). All studies observed a positive association between preoperative depression and all-cause mortality, and in 4 studies the association was statistically significant. Patients with depression had a pooled hazard ratio of 1.46 (95% CI: 1.23-1.73, p<0.0001) for all-cause mortality with moderate heterogeneity (I(2)=50.1%, p=0.061). CONCLUSIONS: This systematic review and meta-analysis indicates that patients with preoperative depression are at increased risk for long-term, all-cause mortality following CABG compared with those without depression. Systematic screening for depression prior to cardiac surgery could identify those at higher risk.

24 Review Prognostic Determinants of Coronary Atherosclerosis in Stable Ischemic Heart Disease: Anatomy, Physiology, or Morphology? 2016

Ahmadi, Amir / Stone, Gregg W / Leipsic, Jonathon / Shaw, Leslee J / Villines, Todd C / Kern, Morton J / Hecht, Harvey / Erlinge, David / Ben-Yehuda, Ori / Maehara, Akiko / Arbustini, Eloisa / Serruys, Patrick / Garcia-Garcia, Hector M / Narula, Jagat. ·From the Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY (A.A., H.H., J.N.) · Columbia University Medical Center, Cardiovascular Research Foundation, New York, NY (G.W.S., A.M.) · University of British Columbia, Vancouver, British Columbia, Canada (A.A., J.L.) · Emory University School of Medicine, Atlanta, GA (L.J.S.) · Walter Reed National Military Medical Center, Bethesda, MD (T.C.V.) · University of California Irvine (M.J.K.) · Lund University, Sweden (D.E.) · University of California San Diego (O.B.-Y.) · Policlinico San Matteo Pavia Fondazione, Pravia, Italy (E.A.) · Imperial College, London, United Kingdom (P.S.) · and Leesburg Regional Medical Centre, FL (H.M.G.-G.). ·Circ Res · Pubmed #27390334.

ABSTRACT: Risk stratification in patients with stable ischemic heart disease is essential to guide treatment decisions. In this regard, whether coronary anatomy, physiology, or plaque morphology is the best determinant of prognosis (and driver an effective therapeutic risk reduction) remains one of the greatest ongoing debates in cardiology. In the present report, we review the evidence for each of these characteristics and explore potential algorithms that may enable a practical diagnostic and therapeutic strategy for the management of patients with stable ischemic heart disease.

25 Review Bioresorbable Stents in PCI. 2016

Lindholm, Daniel / James, Stefan. ·Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden. daniel.lindholm@ucr.uu.se. · Uppsala Clinical Research Center, Dag Hammarskjölds väg 14B, SE-752 37, Uppsala, Sweden. daniel.lindholm@ucr.uu.se. · Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden. · Uppsala Clinical Research Center, Dag Hammarskjölds väg 14B, SE-752 37, Uppsala, Sweden. ·Curr Cardiol Rep · Pubmed #27312934.

ABSTRACT: The evolution of percutaneous coronary intervention has been considerable. Coronary stents were introduced to avoid vessel recoil and reduce acute and late vessel complications. Later, drug-eluting stents were developed to decrease the neointimal hyperplasia associated with bare metal stents in order to reduce restenosis. However, very late stent thrombosis remains problematic, and the permanent presence of a metal stent could be associated with local inflammation and impaired vascular physiology. Thus, bioresorbable stents have been developed, to prevent recoil initially when this risk is the highest, with subsequent degradation over time, to avoid long-term complications of the presence of stents in the coronary vasculature. Here, we review the current status of bioresorbable stents in percutaneous coronary intervention (PCI), with focus on the platforms that have been studied the most: ABSORB, DESolve, and DREAMS. In terms of clinical outcomes, bioresorbable stents have not yet shown superiority compared with current generation drug-eluting stents, but rather a signal of increased stent thrombosis. Further development and longer-term studies are needed before the routine implementation of bioresorbable stents in clinical practice.